SPARTAN (Phase 2 Study): Sparsentan as First-Line Therapy in the Treatment of IgA Nephropathy
SPARTACUS (Phase 2 Study): Sparsentan in Combination With SGLT2 Inhibitors Study Design
EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases
FILSPARI (sparsentan) – PROTECT (Phase 3 Study): Study Design & Results
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
Phase 2 DUET Study Published in the Journal of the American Society of Nephrology
Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
FILSPARI (sparsentan) – Safety Data Sheet
Dual Inhibition of the Endothelin and Angiotensin Receptor Ameliorates Renal and Inner Ear Pathologies in Alport Mice
FILSPARI (sparsentan) – Effect on Proteinuria in Focal Segmental Glomerulosclerosis
Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis
FILSPARI (sparsentan) – Pediatric Patients in Sparsentan FSGS Studies
FILSPARI (sparsentan) – Baseline Characteristics of Asian vs Non-Asian Patients in the PROTECT Study